ACP3 and neoplasm: Thus identification of additional prostate specific tumor antigens, such as PSGR, for T-cell-based immunotherapy is still needed, despite that a number of prostate specific tumor antigens including PSA [12], [13], PSCA [16], PSMA [17]–[19], PAP [20], Prostein [14], [15] and trp-p8 [21], have been identified in the last few years.